CSF3 and anemia (phenotype): Treatment reduction was conducted in 16.0% and 43.6% of the patients with and without baseline anemia (P = 0.0003), and 15.1% and 49.0% of those with and without prophylactic G-CSF administration (P < 0.0001), respectively.